Age, years | 65.3 ± 12.5 |
Male gender | 46 (76.7%) |
Heart failure, aetiology | Â |
   Dilated cardiomyopathy | 27 (45.0%) |
   Ischaemic | 29 (48.3%) |
   Valvular | 3 (5.0%) |
   Congenital | 1 (1.7%) |
Rhythm | Â |
   Sinus | 46 (76.7%) |
   Atrial fibrillation | 13 (21.7%) |
   Atrial flutter | 1 (1.7%) |
Medication | Â |
   Beta-blockers | 43 (71.7%) |
   ACE inhibitors/ARB | 58 (96.7%) |
   Aldosterone antagonists | 39 (65.0%) |
   Loop diuretics | 52 (86.7%) |
   Digoxin | 12 (20.0%) |
   Aspirin | 23 (38.3%) |
   Warfarin | 19 (31.7%) |
   Statin | 30 (50.0%) |
ECG | Â |
   QRS width (ms) | 156 ± 21 |
Heart rate | Â |
   Beats per minute (bpm) | 76 ± 15 |
Blood pressure | Â |
   Systolic (mmHg) | 120 ± 20 |
   Diastolic (mmHg) | 72 ± 13 |
Left ventricle | Â |
   EDV (mL/m2) | 169 ± 62 |
   ESV (mL/m2) | 124 ± 55 |
   EF (%) | 27 ± 8 |
   Mass (g/m2) | 113 ± 30 |
Right ventricle | Â |
   EDV (mL/m2) | 82 (65-123) |
   ESV (mL/m2) | 38 (27-76) |
   EF (%) | 52 (37-62) |
   TAPSE (mm) | 13.5 ± 5.6 |
   Peak wall thickness (mm) | 3.6 ± 0.9 |
Pulmonary artery pressure (mmHg) | 38.7 ± 8.7 |
Late gadolinium enhancement | Â |
   Absent | 20 (33.3%) |
   Subendocardial | 19 (31.7%) |
   Subendocardial + mid-wall | 6 (10.0%) |
   Mid-wall | 15 (25.0%) |
   Right ventricle | 5 (8.3%) |